LAB Standard Biotools Inc
Company Analysis
Latest News
🟢 Standard Biotools is trading 7.65% up in pre-market amid broader risk-on sentiment
Standard Biotools is trading 7.65% up at $0.70 in pre-market, most likely reflecting broader risk-on sentiment. - No fresh company-specific announcement was...
🟢 Standard Biotools is trading 6.44% up today amid XLV's 1.29% gain
Standard Biotools is trading 6.44% up now at $0.69, with healthcare-sector strength appearing to support its rebound from several recent declines. - XLV was...
🔴 Standard Biotools is trading 5.35% down today amid rising Treasury yields
Standard Biotools is trading 5.35% down now at $0.64 amid a broader August 20, 2026 equity pullback linked to rising Treasury yields and renewed bond-market...
🟢 Standard Biotools rises 5.6% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🟢 Standard Biotools is trading 5.74% up in after-hours trading with no clear catalyst identified
Standard Biotools is trading at $0.70, up 5.74% in after-hours trading, with no new company-specific announcement or credible August 18, 2026 catalyst...
🔴 Standard Biotools is trading 5.36% down today with no clear catalyst
Standard Biotools is trading 5.36% down now at $0.67, with no clear company-specific announcement or credible news catalyst identified for August 17, 2026. -...
🔴 Standard Biotools is trading 5.84% down today with no clear company-specific catalyst
Standard Biotools is trading 5.84% down at $0.71, after falling from the August 13 close of $0.75; no fresh company-specific announcement clearly explains the...
🟢 Standard Biotools is trading 7.5% up in after-hours trading amid broad market gains
Standard Biotools is trading at $0.81 (+7.50%) in after-hours trading, with the move appearing aligned with a risk-on market backdrop. - It closed at $0.75 on...
Standard BioTools' second quarter revenue of $20.1M missed estimates as it withdraws full-year guidance.
Standard BioTools reported second quarter revenue of $20.1 million, down 7.6% year-over-year and missing analyst estimates of $20.8 million. The company...
Standard Biotools Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Standard Biotools to report Q2 2026 revenue of $20.80 million and an EPS of -$0.01, with the stock currently trading at approximately $0.87...